BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » bone marrow

Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells

September 19, 2016 By Cade Hildreth (CEO) Leave a Comment

Cesca Therapeutics Stem Cell Patents

Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI

RANCHO CORDOVA, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca’s proprietary methods for the  treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: bone marrow, Cesca Therapeutics, patents

Cord Blood is 2nd Most Common Source of Stem Cells for Cell Therapy

June 22, 2015 By Cade Hildreth (CEO) Leave a Comment

Identifying Hemapoietic Stem Cell Transplant Trends

For those competing within the cord blood marketplace, it is valuable to know that umbilical cord blood is the second most common source of stem cells for cellular therapy.

Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell-based-therapy, both for the treatment of hematological and non-hematological disorders. Indeed, with the recent expansion in stem cell research and an increase in public interest in stem cell-based therapies, researchers are now exploring the potential of umbilical cord blood stem cells for non-hematological disorders.

This is evidenced by the increasing number of clinical trials that are utilizing umbilical cord blood stem cell-based therapies to treat a range of diseases.

However, with these advances come new standards that must be established, including:

  • Standardization of criteria for the selection of umbilical cord blood (UCB) units for stem cell-based therapies
  • Outcome measures
  • Long-term follow-up

Additionally, it is controversial within medical communities to use umbilical cord blood stem cells for non-hematological disorders, a perspective which is gradually starting to change. Clearly, therapeutic use of cord blood stem cells will play an important role in the future of regenerative medicine, but its applications and limitations of use have yet to be defined.

Filed Under: Cord Blood, HSCs Tagged With: bone marrow, cord blood, HSCT

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.